Mainz Biomed NV MYNZ shares are trading lower by 46% to $1.21 during Monday's session has entered a securities purchase agreement with institutional investors to raise $5 million through a registered direct offering.
The agreement involves the sale of ordinary shares (or pre-funded warrants) and warrants, with an effective purchase price of $1.20 per share.
The offering, managed by Titan Partners Group, a division of American Capital Partners, is set to close around November 15, contingent upon meeting customary closing conditions.
See Also: What's Going On With Plug Power Stock?
According to data from Benzinga Pro, MYNZ has a 52-week high of $9.61 and a 52-week low of $1.16.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
